- Home
- NBR vs AGIO Comparison
NBR vs AGIO Comparison
Compare NBR & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBR | AGIO |
|---|---|---|
| Founded | 1952 | 2007 |
| Country | Bermuda | United States |
| Employees | 13900 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | NBR | AGIO |
|---|---|---|
| Price | $92.95 | $29.49 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $75.00 | $38.88 |
| AVG Volume (30 Days) | 243.5K | ★ 750.9K |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | $3.65 | $76.75 |
| Revenue Next Year | $4.88 | $170.73 |
| P/E Ratio | $4.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.03 | $22.24 |
| 52 Week High | $112.90 | $46.00 |
Technical Indicators
Market Signals| Indicator | NBR | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 41.13 | 54.44 |
| Support Level | $75.43 | $26.75 |
| Resistance Level | $92.38 | $30.90 |
| Average True Range (ATR) | 4.67 | 1.09 |
| MACD | -2.06 | 0.28 |
| Stochastic Oscillator | 4.83 | 64.94 |
Price Performance
Historical ComparisonAbout NBR Nabors Industries Ltd.
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.